dc.contributor.author |
Buyuktuna, SA |
|
dc.contributor.author |
Saba, R |
|
dc.contributor.author |
Gozel, MG |
|
dc.contributor.author |
Turhan, O |
|
dc.contributor.author |
Inan, D |
|
dc.contributor.author |
Asik, Z |
|
dc.contributor.author |
Kose, A |
|
dc.date.accessioned |
2022-10-13T10:45:43Z |
|
dc.date.available |
2022-10-13T10:45:43Z |
|
dc.date.issued |
2017 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/78175 |
|
dc.description.abstract |
Introduction: This study was initiated to investigate the risk factors of secondary infections in febrile neutropenic patients following chemotherapy, and to evaluate the clinical, microbiological, and mortality outcomes of these infections. |
|
dc.description.abstract |
Methodology: An evaluation was done on all patients with hematological malignancy who developed a febrile neutropenic episode (FNE) after cytotoxic chemotherapy in the Department of Hematology, Akdeniz University Faculty of Medicine, between January 2007 and December 2008. |
|
dc.description.abstract |
Results: A total of 294 primary FNEs that responded to the initial empirical or targeted treatment were included in the study, and secondary infections developed after 72 (24.5%) of 294 primary FNEs. Risk factors for secondary infections were determined as acute leukemia as the underlying disease, salvage chemotherapy for refractory/relapse diseases, prolonged neutropenia (10 days and over), Multinational Association of Supportive Care in Cancer (MASSC) score < 21, and fungal infection during the primary episode. The mortality rate of patients who developed secondary infections was significantly higher compared to patients without secondary infections (27.8% and 5.4%, respectively; p = 0.001). |
|
dc.description.abstract |
Conclusions: The development of secondary infections in patients with hematological malignancy was not very rare. Greater concern should be shown for these infections to increase patient survival rates. |
|
dc.description.abstract |
C1 [Buyuktuna, Seyit Ali; Gozel, Mustafa Gokhan] Cumhuriyet Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Sivas, Turkey. |
|
dc.description.abstract |
[Saba, Rabin] Medstar Antalya Hosp Ctr, Dept Infect Dis & Clin Microbiol, Antalya, Turkey. |
|
dc.description.abstract |
[Turhan, Ozge; Inan, Dilara] Akdeniz Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Antalya, Turkey. |
|
dc.description.abstract |
[Asik, Zahide] Tokat State Hosp, Dept Infect Dis & Clin Microbiol, Tokat, Turkey. |
|
dc.description.abstract |
[Kose, Adem] Inonu Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Malatya, Turkey. |
|
dc.source |
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES |
|
dc.title |
Secondary infections after cytotoxic chemotherapy in patient with |
|
dc.title |
hematological malignancies |
|